Insights from Medical Experts
Watch videos and read the latest clinical perspectives on PNH
Hear what PNH medical experts have to say about FABHALTA
.
Who Is an Appropriate Patient for FABHALTA?
PNH medical experts share their experience treating patients with FABHALTA, empowering you to make informed decisions in your practice.
Beyond Hemoglobin Stabilization: Impact of FABHALTA in Adults With PNH
Join expert hematologists as they discuss changing PNH treatment goals and their use of FABHALTA in adults with PNH. This conversation examines clinical data that will help hematologists determine which patients may be appropriate to switch to FABHALTA.
The Clinical Data Behind FABHALTA
Hear medical experts as they discuss the clinical data for FABHALTA and what this can mean for adult patients with PNH.
Medical Experts Discuss the Use of FABHALTA
Hear from medical experts as they discuss their approach to treating PNH.
Your Questions About FABHALTA Answered
Hear from a panel of experts as they discuss frequently asked questions about FABHALTA.
The medical experts featured in the above videos were compensated for their time by Novartis Pharmaceuticals Corporation.
Read the latest clinical perspectives on PNH
.
Discover FABHALTA, the First and Only FDA-Approved Oral Monotherapy for the Treatment of Adults With Paroxysmal Nocturnal Hemoglobin (PNH)
PNH medical experts, Dr. Lawrence Rice and Dr. Ilene Weitz, discuss PNH and the clinical data behind FABHALTA.
Optimizing PNH Management: A Case Study of an Adult Patient Who Switched to FABHALTA
A physician shares his real-world experience of switching a patient to FABHALTA, providing insights into his conversations on why FABHALTA was the right treatment choice for his adult patient with PNH.
Adopting FABHALTA Into Clinical Practice
Physicians discuss their personal experiences with prescribing FABHALTA and key considerations for adopting FABHALTA into any clinical practice.
Exploring the Switch to FABHALTA for Adult Patients With PNH
Dr. Majerus discusses the clinical data of FABHALTA and provides key considerations when switching patients who were previously on a C5i (eculizumab or ravulizumab) to FABHALTA. She also shares best practices on monitoring patients taking FABHALTA.
The medical experts featured in these newsletters were compensated for their time by Novartis Pharmaceuticals Corporation.